ʻO Rosuvastatin Calcium
瑞舒伐他汀钙 | ʻO Rosuvastatin Calcium | 147098-20-2 | I-Hale/CEP |
RSM(Crystal) | 147118-40-9 | I-Hale | |
RSM(Kūpono) | 147118-40-9 | I-Hale | |
RSP | — | I-Hale | |
RS-8 | 147118-36-3 | I-Hale | |
RS-8-1 | 147118-37-4 | I-Hale | |
TP-8 | 131466-61-0 | I-Hale | |
TP-11 | 147118-35-2 | I-Hale | |
TP-13 | 147118-39-6 | I-Hale | |
RS-10 | 289042-12-2 | I-Hale | |
RS-11 | 355806-00-7 | I-Hale |
wehewehe
ʻO Rosuvastatin Calcium (BANM, JAN, USAN) ʻike ʻia ʻo Rosuvastatin ma US.a me kahi mea hoʻokūkū hoʻokūkū HMG-CoA reductase me kahi IC50 o 11 nM[1].Hoʻopaʻa ikaika ʻo Rosuvastatin Calcium i ke kanaka ether-a-go-go related gene (hERG) i kēia manawa me kahi IC50 o 195 nM, hoʻopaneʻe i ka repolarization cardiac, a no laila e hoʻolōʻihi ʻia ai ka lōʻihi o ka hana (APDs) a me ka hoʻoponopono ʻana i ka manawa QT (QTc) [2].Hoʻemi ʻo Rosuvastatin Calcium i ka hōʻike ʻana o ka hERG makua a me ka launa pū ʻana o ka protein haʻalulu wela 70 (Hsp70) me ka protein hERG.He mea maikaʻi loa ka Rosuvastatin Calcium i ka hoʻohaʻahaʻa ʻana i ka lipoprotein haʻahaʻa haʻahaʻa (LDL) cholesterol, triglycerides, a me nā pae protein C-reactive [3].
ʻIke hou aʻe e pili ana i nā hui inoa lāʻau: International Nonproprietary Names.
Hoʻolaha Nui: Aia ka ʻikepili honua ʻo Drugs.com ma ka hoʻokuʻu BETA.ʻO ia ke ʻano o ka hoʻomohala ʻana a loaʻa paha nā hewa.ʻAʻole i manaʻo ʻia ma ke ʻano he pani no ka ʻike a me ka hoʻoholo ʻana o kāu kauka, lāʻau lapaʻau a i ʻole nā mea mālama ola kino ʻē aʻe.ʻAʻole pono e manaʻo ʻia he palekana, kūpono a maikaʻi paha ka hoʻohana ʻana i kekahi lāʻau lapaʻau ma kekahi ʻāina.E kūkākūkā me kāu kauka mālama ola ma mua o ka lawe ʻana i kekahi lāʻau lapaʻau.
I ka US, ʻo Rosuvastatin (rosuvastatin systemic) he lālā o ka papa lāʻau statins a hoʻohana ʻia e mālama i ka Atherosclerosis, High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa - Elevated LDL, Hyperlipoproteinemia Type. IIb - LDL VLDL kiʻekiʻe, Hyperlipoproteinemia Type III - Elevated beta-VLDL IDL, Hyperlipoproteinemia Type IV - Kiʻekiʻe VLDL, Hypertriglyceridemia a me ka pale ʻana i ka maʻi cardiovascular.
Ka hope
He mea hoʻopaʻapaʻa koho a hoʻokūkū o HMG-CoA reductase, ʻo ia hoʻi he antilipemic.
Waihona
Pauda | -20°C | 3 makahiki |
4°C | 2 makahiki | |
I ka solvent | -80°C | 6 mahina |
-20°C | 1 mahina |
ʻO ke kinona
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.